Welcome to our dedicated page for APOLLOMICS news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology drug candidates for difficult-to-treat and treatment-resistant cancers. Its recurring updates center on vebreltinib (APL-101), a selective c-Met inhibitor being developed for non-small cell lung cancer and other tumors with c-Met alterations, along with pipeline assets that include targeted therapies, immuno-oncology candidates and other novel oncology mechanisms.
Company news also covers financial results, financing actions, collaborations for development and commercialization, board and committee changes, auditor and listing-status matters, operational continuity, and litigation-related resolutions. These updates connect Apollomics' clinical programs with its cash resources, governance, public-market status and partner agreements.
Summary not available.
Summary not available.
Summary not available.
Apollomics Inc. (Nasdaq: APLM, APLMW) announced that Co-Founder and President, Sanjeev Redkar, will present at the 23rd Annual R. Bryan Miller Symposium on April 14, 2023, at UC Davis. Dr. Redkar's talk, titled 'The HGF/cMet Pathway in Cancer – Early Development to Clinical Evidence', will highlight the significance of the HGF/cMet pathway in cancer progression and treatment resistance. This pathway is crucial due to its association with gene mutations that drive tumor growth. Apollomics is advancing APL-101, a selective c-Met inhibitor aimed at treating non-small cell lung cancer and brain tumors. Additional notable speakers include Paula T. Hammond from MIT and David R. Liu from Harvard. Details about the symposium and speaker schedule are available on the UC Davis site.
On March 30, 2023, Apollomics Inc. successfully listed on Nasdaq under the symbol APLM through a SPAC merger with Maxpro Capital Acquisition Corp. The IPO opened at $18.60, a 172% increase from the issue price of $10.00, resulting in a market cap of $2.6 billion. Founded in 2015, Apollomics focuses on developing innovative oncology therapies, with six of its nine drug candidates currently in clinical stages. The company has achieved significant milestones, including Orphan Drug Designation for vebreltinib (APL-101) for non-small cell lung cancer. It also has Breakthrough Therapy Designation for uproleselan (APL-106) in acute myeloid leukemia, with Phase 3 patient recruitment expected to complete this year.
Apollomics Inc. has completed its business combination with Maxpro Capital Acquisition Corp., allowing its Class A ordinary shares and public warrants to start trading on the Nasdaq Capital Market under the ticker symbols APLM and APLMW as of March 30, 2023. The deal, approved by Maxpro’s shareholders, raised $23.65 million through a private investment in public equity (PIPE) financing, enhancing Apollomics' capacity to develop its oncology pipeline, which includes nine drug candidates. The company aims to address treatment-resistant cancers and expects critical clinical trial results this year that could support regulatory filings.